Epigenome-wide methylation study identified 2 novel CpGs associated with T2DM risk and a network of co-methylated CpGs capable of patient's classifications.

Abstract

Prevention of Type 2 diabetes mellitus (T2DM) pandemic needs markers that can precisely predict the disease risk in an individual. Alterations in DNA methylations due to exposure towards environmental risk factors are widely sought markers for T2DM risk prediction. To identify such individual DNA methylation signatures and their effect on disease risk, we performed an epigenome-wide association study (EWAS) in 844 Indian individuals of Indo-European origin. We identified and validated methylation alterations at 2 novel CpG sites in MIR1287 (cg01178710), and EDN2-SCMH1 (cg04673737) genes associated with T2DM risk at the epigenome-wide-significance-level (p < 1.2x10-7). Further, we also replicated the association of 2 known CpG sites in TXNIP, and CPT1A in the Indian population. With 535 EWAS significant CpGs (p < 1.2x10-7) identified in the discovery phase samples, we created a co-methylation network using weighted correlation network analysis and identified 4 modules among the CpGs. We observed that methylation of one of the module associates with T2DM risk factors (e.g. BMI, insulin, C-peptide) and can be used as markers to segregate T2DM patients with good glycemic control (e.g. low HbA1c) and dyslipidemia (low HDL and high TG) from the other patients. Additionally, an intronic SNP (rs6503650) in the JUP gene, a member of the same module, associated with methylation at all the 14 hub CpG sites of that module as methQTL. Our network-assisted epigenome-wide association study is the first to systematically explore DNA methylation variations conferring risks to T2DM in Indians and use the identified risk CpG sites for patient segregation with different clinical outcomes. These findings can be useful for better stratification of patients to improve the clinical management and treatment effects.